HK1142276A1 - Methods for treating bleeding disorders using sulfated polysaccharides - Google Patents

Methods for treating bleeding disorders using sulfated polysaccharides

Info

Publication number
HK1142276A1
HK1142276A1 HK10108794.9A HK10108794A HK1142276A1 HK 1142276 A1 HK1142276 A1 HK 1142276A1 HK 10108794 A HK10108794 A HK 10108794A HK 1142276 A1 HK1142276 A1 HK 1142276A1
Authority
HK
Hong Kong
Prior art keywords
methods
sulfated polysaccharides
bleeding disorders
treating bleeding
treating
Prior art date
Application number
HK10108794.9A
Other languages
English (en)
Chinese (zh)
Inventor
Kirk W Johson
Original Assignee
巴克斯特國際公司
巴克斯特醫療保健股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯特國際公司, 巴克斯特醫療保健股份有限公司 filed Critical 巴克斯特國際公司
Publication of HK1142276A1 publication Critical patent/HK1142276A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10108794.9A 2004-05-27 2010-09-16 Methods for treating bleeding disorders using sulfated polysaccharides HK1142276A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27

Publications (1)

Publication Number Publication Date
HK1142276A1 true HK1142276A1 (en) 2010-12-03

Family

ID=35462725

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07107845.5A HK1103624A1 (en) 2004-05-27 2007-07-20 Methods for treating bleeding disorders using sulfated polysaccharides
HK10108794.9A HK1142276A1 (en) 2004-05-27 2010-09-16 Methods for treating bleeding disorders using sulfated polysaccharides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07107845.5A HK1103624A1 (en) 2004-05-27 2007-07-20 Methods for treating bleeding disorders using sulfated polysaccharides

Country Status (16)

Country Link
US (4) US7767654B2 (xx)
EP (2) EP1748781B1 (xx)
JP (2) JP5232470B2 (xx)
CN (2) CN103251647A (xx)
AU (1) AU2005249465B2 (xx)
BR (1) BRPI0511603A (xx)
CA (1) CA2567495C (xx)
CY (1) CY1113705T1 (xx)
DK (1) DK1748781T3 (xx)
ES (2) ES2399277T3 (xx)
HK (2) HK1103624A1 (xx)
PL (1) PL1748781T3 (xx)
PT (1) PT1748781E (xx)
RU (1) RU2347574C2 (xx)
SI (1) SI1748781T1 (xx)
WO (1) WO2005117912A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
RU2347574C2 (ru) * 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
CA2648533A1 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides
ES2476250T3 (es) * 2007-02-23 2014-07-14 Baxter International Inc. Métodos de procedimiento de purificación de fucoidano a partir de extractos de algas marinas
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
JP5896742B2 (ja) * 2008-08-22 2016-03-30 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 出血性障害を処置するための方法
US9566364B2 (en) * 2008-12-11 2017-02-14 Baxter International Inc. Preparations based on fibrinogen and sulfated polysaccharides
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
AU2011205271B2 (en) * 2010-01-14 2014-01-30 Baxalta GmbH Methods and compositions for treating bleeding disorders
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
DK2947148T3 (en) * 2010-04-20 2017-09-18 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
AU2011313505B2 (en) 2010-10-06 2015-09-17 Medimmune Limited Factor II and fibrinogen for treatment of haemostatic disorders
EP2734213B1 (en) * 2011-07-19 2018-06-06 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013116383A1 (en) 2012-01-30 2013-08-08 Baxter International Inc. Non-anticoagulant sulfated or sulfonated synthetic polymers
JP6228137B2 (ja) 2012-01-30 2017-11-08 バクスアルタ ゲーエムベーハー 非抗凝固性の硫酸化またはスルホン酸化多糖
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CA2881785A1 (en) * 2012-08-14 2014-02-20 Baxter International Inc. Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
WO2018043666A1 (ja) * 2016-08-31 2018-03-08 王子ホールディングス株式会社 酸性キシロオリゴ糖の製造方法
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
SG11201911318SA (en) 2017-05-31 2020-01-30 Oji Holdings Corp Moisturizing topical preparation
BR112020004787A2 (pt) 2017-09-12 2020-09-24 Oji Holdings Corporation polissulfato de pentosano, composição farmacêutica, anticoagulante, e, método para produzir polissulfato de pentosano
PL3730521T3 (pl) 2017-12-20 2023-10-09 Oji Holdings Corporation Polisiarczan pentozanu i lek zawierający polisiarczan pentozanu
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
ATE121139T1 (de) * 1990-11-05 1995-04-15 Baxter Diagnostics Inc Verfahren zur bestimmung der konzentration von antikoagulantien.
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
CA2217746C (en) * 1995-04-28 2000-04-04 Takara Shuzo Co., Ltd. Sugar compounds
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
JP2002506515A (ja) * 1997-04-25 2002-02-26 ペンタファルム アクチェンゲゼルシャフト 蛋白質ｃ−系における障害の機能的検出法
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
JP4261071B2 (ja) * 1999-04-15 2009-04-30 タカラバイオ株式会社 治療剤
AU2001244602A1 (en) * 2000-03-30 2001-10-15 Ajinomoto Co. Inc. Drugs retained in target tissue over long time
PL365290A1 (en) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
DE60202427T2 (de) * 2001-10-24 2005-12-29 Takara Bio Inc., Otsu Sulfatiertes Fucan-Oligosaccharid
JP3941036B2 (ja) 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
RU2347574C2 (ru) * 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
CA2648533A1 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides

Also Published As

Publication number Publication date
EP1748781A4 (en) 2008-07-02
CA2567495C (en) 2014-02-18
US20050282771A1 (en) 2005-12-22
US20120129777A1 (en) 2012-05-24
US20110237512A1 (en) 2011-09-29
CN103251647A (zh) 2013-08-21
PT1748781E (pt) 2013-01-22
CY1113705T1 (el) 2016-06-22
EP1748781B1 (en) 2012-12-19
EP1748781A1 (en) 2007-02-07
WO2005117912A1 (en) 2005-12-15
CN1984664B (zh) 2013-07-24
HK1103624A1 (en) 2007-12-28
US20090269325A1 (en) 2009-10-29
AU2005249465B2 (en) 2007-12-06
JP5232470B2 (ja) 2013-07-10
AU2005249465A1 (en) 2005-12-15
US8771973B2 (en) 2014-07-08
RU2347574C2 (ru) 2009-02-27
PL1748781T3 (pl) 2013-05-31
EP2165711A1 (en) 2010-03-24
JP2012046551A (ja) 2012-03-08
US7767654B2 (en) 2010-08-03
RU2006146801A (ru) 2008-07-10
SI1748781T1 (sl) 2013-03-29
BRPI0511603A (pt) 2008-01-02
DK1748781T3 (da) 2013-02-11
EP2165711B1 (en) 2014-05-21
CN1984664A (zh) 2007-06-20
JP2008500367A (ja) 2008-01-10
ES2482105T3 (es) 2014-08-01
ES2399277T3 (es) 2013-03-27
US8859526B2 (en) 2014-10-14
US7829549B2 (en) 2010-11-09
CA2567495A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
HK1142276A1 (en) Methods for treating bleeding disorders using sulfated polysaccharides
EP1855710A4 (en) MUSCLE REGENERATION
IL183889A0 (en) Treatment method
PT1805312E (pt) Processos e meios para produzir hialurano
GB0526291D0 (en) Therapeutic method
IL186408A0 (en) Combination treatment methods
EP1797020A4 (en) GUANIDINE POLYSACCHARIDES, THEIR USE AS ABSORBENTS AND PROCESS FOR THE PRODUCTION THEREOF
IL182011A0 (en) Treatment screening methods
IL183985A0 (en) Methods for treating autoimmune disorders
EP1912658A4 (en) THERAPEUTIC PROTOCOLS WITH HYALURONANE
GB0525957D0 (en) Methods
EP1755670A4 (en) METHODS FOR TREATING VASCULAR DISEASES
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
PT1686201E (pt) Aparelho de pulling-down
EP1952821A4 (en) THERAPEUTIC AGENT FOR REGENERATING THE DENTIN-PULPA COMPLEX
EP1942909A4 (en) METHODS OF TREATING RESPIRATORY DISORDERS
GB0502171D0 (en) Well treatment
EP1928498A4 (en) METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
ZA200709915B (en) Methods for treating fibrotic conditions
GB0518425D0 (en) Methods
GB0516204D0 (en) Methods
GB0513777D0 (en) Methods for tissue engineering
ZA200803971B (en) Improved methods and means for producing hyaluronan